Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Short-term Investments (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Short-term Investments for 13 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 1.8% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 1.8% year-over-year, with the annual reading at $5.1 million for FY2025, 1.8% up from the prior year.
  • Short-term Investments for Q4 2025 was $5.1 million at Madrigal Pharmaceuticals, down from $814.1 million in the prior quarter.
  • The five-year high for Short-term Investments was $814.1 million in Q3 2025, with the low at $5.0 million in Q4 2024.
  • Average Short-term Investments over 5 years is $313.8 million, with a median of $234.1 million recorded in 2021.
  • The sharpest move saw Short-term Investments plummeted 88.37% in 2022, then surged 349.77% in 2024.
  • Over 5 years, Short-term Investments stood at $234.1 million in 2021, then tumbled by 88.37% to $27.2 million in 2022, then surged by 525.51% to $170.3 million in 2023, then plummeted by 97.06% to $5.0 million in 2024, then rose by 1.8% to $5.1 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $5.1 million, $814.1 million, and $610.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.